Ülke: Avustralya
Dil: İngilizce
Kaynak: Department of Health (Therapeutic Goods Administration)
ciprofloxacin hydrochloride
Bayer Australia Ltd
Registered
CIPROXIN TABLETS CMI VX1.0 1 CIPROXIN ® TABLETS (CI·PROX·IN) _ciprofloxacin_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Ciproxin tablets. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Ciproxin tablets against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT CIPROXIN IS USED FOR Ciproxin tablets are used for the treatment of infections of the lungs, skin, bones, joints, kidneys, bladder, prostate and bowel. Ciproxin is also used to treat inhalational anthrax (an infection caused by breathing in the spores of bacteria). Ciproxin tablets contain the active ingredient, CIPROFLOXACIN , which is an antibiotic belonging to a group of medicines called quinolones (pronounced kwin-o-lones). These antibiotics work by killing the bacteria that are causing your infection. Ciproxin will not work against infections caused by viruses such as colds or the flu. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. BEFORE YOU TAKE CIPROXIN _WHEN YOU MUST NOT TAKE IT _ DO NOT TAKE CIPROXIN IF YOU HAVE AN ALLERGY TO: • ciprofloxacin, the active ingredient in Ciproxin • any of the ingredients listed at the end of this leaflet • other medicines belonging to the quinolone chemical family (e.g. moxifloxacin, norfloxacin, nalidixic acid). Some of the symptoms of an allergic reaction may include: • shortness of breath • wheezing or difficulty breathing • swelling of the face, lips, tongue or other parts of the body • rash, itching or hives on the skin. DO NOT TAKE CIPROXIN IF YOU ARE ALSO TAKING A MEDICINE CALLED TIZANIDINE, A MUSCLE RELAXANT USED TO TREAT SPAS Belgenin tamamını okuyun
AUSTRALIAN PRODUCT INFORMATION CIPROXIN® (CIPROFLOXACIN) TABLETS Ciproxin® PI VX1.0; CCDS 20 Page 1 of 19 1 NAME OF THE MEDICINE Ciprofloxacin 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Ciproxin is available as 250 mg, 500 mg and 750 mg film-coated tablets for oral administration. Ciproxin 250 contains 250mg of active, Ciproxin 500 contains 500mg of active, and Ciproxin 750 contains 750mg of active. For the full list of excipients, see SECTION 6.1 LIST OF EXCIPIENTS. 3 PHARMACEUTICAL FORM Ciproxin 250 – Biconvex, white film-coated tablet round tablet 11mm in diameter containing 250 mg ciprofloxacin, the top scored and marked with "CIP” on one half of the score and “250" on the other half and the Bayer cross on bottom. Ciproxin 500 – Biconvex, oblong 18mm x 8mm, white film-coated tablet containing 500 mg ciprofloxacin, the top scored and marked with "CIP and 500" on the other side separated by a score across the width of the tablet and "BAYER" on bottom. Ciproxin 750 – Biconvex, 22mm x 8mm oblong, white film-coated tablet containing 750 mg ciprofloxacin, and marked with "CIP 750" on top and "BAYER" on bottom. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ciproxin is indicated for the treatment of infections caused by susceptible organisms in the conditions listed below: Urinary tract infections Gonorrhoeal urethritis and cervicitis Gastroenteritis Bronchial Infections Skin and skin structure infections Bone and joint infections Chronic bacterial prostatitis of mild to moderate severity Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized _Bacillus anthracis._ Ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. NOTE: 1. Typhoid and Paratyphoid infections and infections due to multi-resistant _ Staphylococcus _ _aureus_ are excluded from the above due to insufficient data. Ciproxin® PI VX1.0; CCDS 20 Page 2 of 1 Belgenin tamamını okuyun